ValueScreener

ValueScreener company report

Innate Pharma S.A. (IPHA)

NASDAQ / Healthcare / Biotechnology

Share price

1.48 USD Market dataClose of Oct 15, 2026

Market capitalisation

157.9M USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Apr 1, 2026
Ratios computed
Oct 15, 2026
Filed years
9, FY2017 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on invested capital, after tax

n/a Computed

From the FY2025 filing

Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

Read quality

Valuation

Price to earnings

n/m Computed

FY2025 accounts, priced at the latest close

Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

Read valuation

Cash generation

Free cash flow yield

-37.6% Computed

FY2025 accounts, priced at the latest close

Read cash generation

Revenue and net income, by fiscal year

FY2016 Revenue: 56.2M EURFY2016 Net income: 12.6M EURFY2017 Revenue: 44.0M EURFY2017 Net income: -48.4M EURFY2018 Revenue: 94.0M EURFY2018 Net income: 3.0M EURFY2019 Revenue: 85.4M EURFY2019 Net income: -20.8M EURFY2020 Revenue: 69.8M EURFY2020 Net income: -64.0M EURFY2021 Revenue: 24.7M EURFY2021 Net income: -52.8M EURFY2022 Revenue: 57.7M EURFY2022 Net income: -58.1M EURFY2023 Revenue: 61.6M EURFY2023 Net income: -7.6M EURFY2024 Revenue: 20.1M EURFY2024 Net income: -49.5M EURFY2025 Revenue: 9.0M EURFY2025 Net income: -49.2M EUR
Revenue Net income10 fiscal years; a year whose statement names no SEC filing is market data, and the table in Filings says which.
Named tests met
0 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it cheap

Free cash flow yield is -37.6% at the close of 2026-10-15 on FY2025 figures; the lines are 2.0%, 5.0% and 8.0%, set by convention, and this sits below the lowest.

Today, against the Biotechnology industry (427 companies), -37.6% sits at the 42nd percentile; the middle half of that group runs from -91.4% to -6.2%.

Is it safe

Current ratio was 1.27 in FY2025, in the band labelled "Tight" (1.00 to 1.50), on lines anchored on Graham's defensive-investor criteria.

Today, against the Biotechnology industry (556 companies), 1.27 sits at the 12th percentile; the middle half of that group runs from 2.39 to 9.18.

Year by year against peers
Whether Innate Pharma S.A.'s operating margin stayed above the median of the Biotechnology industry, year by year. (FY2016 to FY2025, 10 fiscal years of Innate Pharma S.A. with a comparable figure)
The direction
Which way Innate Pharma S.A.'s operating margin has moved, and how steadily. (FY2016 to FY2025, 10 filed years of Innate Pharma S.A.)
What could explain it
What in Innate Pharma S.A.'s filed statements could explain the movements. (3 readings drawn from the statement lines Innate Pharma S.A. filed)
What to check next
What to check next on Innate Pharma S.A., and where in its filings. (3 questions for Innate Pharma S.A.)
In one paragraph
One paragraph on Innate Pharma S.A.'s returns, cash, balance sheet and price. (5 of sixteen figures read for Innate Pharma S.A.)

These are IPHA’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research IPHAPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 20-F, filed Apr 1, 2026, accession 0001598599-26-000005.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

Innate Pharma S.A: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

n/a ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Return on equity
Why n/m

Book equity is zero or negative. Return on equity computed over it flips sign and can read as a strong positive on a loss-making company, so we will not show a number.

n/m ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Return on capital employed, pre-tax-207.2% ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Return on assets-78.4% ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Gross margin
Why n/a

Our archived statements for this filer carry no gross profit line, so there is nothing to compute a gross margin from and trace back to source. That may be because the filer presents no cost of revenue, or because we have not captured the concept. We do not guess which.

n/a ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Operating margin-599.8% ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Net margin-546.1% ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
IPHA -546.1%
PRLD -819.6%IVA -2002.7%STRO -186.4%MDWD -140.8%IMDX -1238.5%
-2002.7%-140.8%
Net margin: IPHA against the 5 companies named under Valuation context, each as filed for its own latest year. Placement only: no average is drawn.

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

Innate Pharma S.A: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity
Why n/m

Filed shareholders equity is zero or below, so debt measured against it is not a measurement (n/m).

n/m ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Current ratio1.27 ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Quick ratio1.27 ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Interest coverage
Why n/m

Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).

n/m ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Altman Z-score
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Net debt
Why n/a

The FY2025 balance sheet carries no net debt we could read.

n/a ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Total assets 62.7MTotal liabilities 84.4MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity (zero or below, not drawn)
The balance sheet, line by line

Financial health

What Innate Pharma S.A owned and owed at the end of fiscal 2025, from the balance sheet it filed (20-F, filed Apr 1, 2026, 0001598599-26-000005).

Innate Pharma S.A: balance sheet position
Total assets62.7M FiledFY2025 20-F, filed Apr 1, 2026
Total liabilities84.4M FiledFY2025 20-F, filed Apr 1, 2026
Shareholders' equity-21.7M FiledFY2025 20-F, filed Apr 1, 2026
Cash28.1M FiledFY2025 20-F, filed Apr 1, 2026
Total debtn/a FiledFY2025 20-F, filed Apr 1, 2026
Net debtn/a
Current ratio1.27
Debt to equityn/m
  • Debt to equity: FY2025: Filed shareholders equity is zero or below, so debt measured against it is not a measurement (n/m).
  • Interest cover: FY2025: Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

Innate Pharma S.A: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
P/E on trailing twelve months
Why n/a

A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

n/a ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book
Why n/m

Book equity is zero or negative, so a ratio measured against it (debt to equity, price to book) is not a measurement, and we will not show a number.

n/m ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Price to sales15.64x ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Enterprise value to EBIT
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Enterprise value to EBITDA
Why n/m

EBITDA is zero or negative, so a multiple of it is not meaningful.

n/m ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Diluted earnings per share
Why n/a

The FY2025 filing carries no diluted earnings per share we could read.

n/a FiledFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005

We publish no fair value or price target of our own. Value IPHA on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for Innate Pharma S.A today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

Innate Pharma S.A: valuation
Share price1.48 USD
Market capitalisation157.9M USD
Enterprise value to EBITDAn/m
Graham numbern/m
Diluted earnings per share, FY2016n/a

Price to earnings on trailing twelve months: A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

Companies like Innate Pharma S.A

  1. Prelude Therapeutics Incorporated (PRLD)Market cap 192.2M USD
  2. Inventiva S.A. (IVA)Market cap 161.7M USD
  3. Sutro Biopharma, Inc. (STRO)Market cap 190.0M USD
  4. MediWound Ltd. (MDWD)Market cap 157.6M USD
  5. Insight Molecular Diagnostics Inc. (IMDX)Market cap 100.1M USD

Same industry (Biotechnology) and size band (Micro, 50M to 300M), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

Innate Pharma S.A: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield-37.6% ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Free cash flow-52.9M EUR ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Free cash flow margin-587.4% ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
FY2016 Free cash flow: -46.2M EURFY2016 Net income: 12.6M EURFY2017 Free cash flow: -51.0M EURFY2017 Net income: -48.4M EURFY2018 Free cash flow: -33.4M EURFY2018 Net income: 3.0M EURFY2019 Free cash flow: 33.7M EURFY2019 Net income: -20.8M EURFY2020 Free cash flow: -52.7M EURFY2020 Net income: -64.0M EURFY2021 Free cash flow: -59.4M EURFY2021 Net income: -52.8M EURFY2022 Free cash flow: -19.7M EURFY2022 Net income: -58.1M EURFY2023 Free cash flow: -32.9M EURFY2023 Net income: -7.6M EURFY2024 Free cash flow: -7.3M EURFY2024 Net income: -49.5M EURFY2025 Free cash flow: -52.9M EURFY2025 Net income: -49.2M EUR
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

Innate Pharma S.A.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/aFY2025Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
-37.6%FY2025Oct 15, 2026
n/aFY2025Apr 1, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
n/aFY2025Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
n/mFY2025Apr 1, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
1.27FY2025Apr 1, 2026
15.64xFY2025Oct 15, 2026
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/aFY2025Oct 15, 2026
n/a We hold no figure here and no stored reason for its absence. The gap is ours, not the company's.
0.53FY2025Apr 1, 2026
0/9FY2025Apr 1, 2026

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 9 filed fiscal years on record, FY2017 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 fiscal years, FY2016 to FY2025. 9 read from the annual reports Innate Pharma S.A filed with the SEC, each naming its filing; the rest from statements that name none, which are market data. Amounts in EUR, as reported.

Innate Pharma S.A: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY20259.0M-54.0M-49.2Mn/a-52.9M-599.8%n/m20-F, Apr 1, 20260001598599-26-000005
FY202420.1M-51.6M-49.5Mn/a-7.3M-256.3%-560.0%20-F, Apr 30, 20250001598599-25-000042
FY202361.6M-12.7M-7.6Mn/a-32.9M-20.6%-14.6%20-F, Apr 4, 20240001598599-24-000020
FY202257.7M-57.4M-58.1Mn/a-19.7M-99.6%-107.3%20-F, Apr 6, 20230001628280-23-010946
FY202124.7M-47.8M-52.8Mn/a-59.4M-193.6%-49.1%20-F, Apr 4, 20220001628280-22-008197
FY202069.8M1.1M-64.0Mn/a-52.7M1.6%-41.0%20-F, Apr 27, 20210001628280-21-007629
FY201985.4M1.6M-20.8Mn/a33.7M1.8%-9.6%20-F, Apr 24, 20200001171843-20-002847
FY201894.0M5.1M3.0Mn/a-33.4M5.5%1.8%20-F, Apr 24, 20200001171843-20-002847
FY201744.0M-40.0M-48.4Mn/a-51.0M-90.8%-48.7%20-F, Apr 24, 20200001171843-20-002847
FY201656.2M7.6M12.6M0.23-46.2M13.5%14.7%Market data, supplied Oct 15, 2026accession n/a
  • Revenue, compound annual growth FY2016 to FY2025: -18.4%
  • Earnings: Earnings was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Fewer than two filed years carry earnings per share.
  • Free cash flow: Free cash flow was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

Innate Pharma S.A: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score0.53 ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Piotroski F-score0/9 ComputedFY2025 20-F, filed Apr 1, 2026, 0001598599-26-000005
Named tests met0 of 30 Computed
Beta0.73 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 0 met, 15 not met, 15 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
None of the named tests.
Does not
Defensive investor (Benjamin Graham); Large cap, low P/E; Three forensic scores; High returns and growth; Gross margin, turnover (Robert Novy-Marx); High yield, low payout; Dividends and buybacks; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Tangible book or below; Cash-flow yield and ROIC
Not measured
Deep value; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Low PEG, low debt (Peter Lynch); EV/EBITDA and coverage; Low beta, profitable; ROIC at or above WACC; P/E times P/B (Benjamin Graham); High returns, low debt; Book or below, low debt (Walter Schloss); Cash-covered dividend; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Cheapest quarter on P/B (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(22)
  • Debt to Equity: Filed shareholders equity is zero or below, so debt measured against it is not a measurement (n/m).
  • Positive Earnings Streak: The latest filed year has no per-share earnings we can read; the test needs 10.
  • P/B Ratio: Book equity is zero or negative, so a ratio measured against it (debt to equity, price to book) is not a measurement, and we will not show a number.
  • Piotroski F-Score: The stored figure is a zero that can stand for data we do not hold, so this test is not measured.
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
  • Return on Invested Capital: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Altman Z-Score: We do not hold this figure for this company, so there is nothing to show.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • Return on Equity: Book equity is zero or negative. Return on equity computed over it flips sign and can read as a strong positive on a loss-making company, so we will not show a number.
  • Gross Margin: Our archived statements for this filer carry no gross profit line, so there is nothing to compute a gross margin from and trace back to source. That may be because the filer presents no cost of revenue, or because we have not captured the concept. We do not guess which.
  • EV/EBITDA: EBITDA is zero or negative, so a multiple of it is not meaningful.
  • Interest Coverage: Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Share Count Change Yoy: We do not hold this figure for this company, so there is nothing to show.
  • ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.
  • Price Tangible Book: Book equity is zero or negative, so a ratio measured against it (debt to equity, price to book) is not a measurement, and we will not show a number.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by the founder: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 22 figures could not be read on this company, among them Debt to Equity, Positive Earnings Streak, P/B Ratio. Each blank in the table above names the rest, with its reason. 15 named tests come back incomplete because of them, which is neither met nor missed.
  • We hold 9 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy